laminopathy type Decaudain-Vigouroux

Summary

laminopathy type Decaudain-Vigouroux (MONDO:0015308) is a disease. A subtype of hyperlipidemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	laminopathy type Decaudain-Vigouroux
Mondo ID	MONDO:0015308
Orphanet	137871
ICD-11	815630778
SNOMED CT	724205009
UMLS	C4518324
MedGen	1375333
Is cancer (heuristic)	no

Also known as: laminopathy with severe metabolic syndrome and myopathy

Disease family

This is a subtype of hyperlipidemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › metabolic disease › hyperlipidemia › laminopathy type Decaudain-Vigouroux

Related subtypes (2): familial hyperlipidemia, hyperalphalipoproteinemia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.